¼¼°èÀÇ mRNA ¹é½Å ¹× Ä¡·áÁ¦ ½ÃÀå ±Ô¸ð Á¶»ç : ¹é½Å À¯Çüº°, ¿ëµµº°, Ä¡·á À¯Çüº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° ¿¹Ãø(2022-2032³â)
Global mRNA Vaccines and Therapeutics Market Size Study, by Vaccine Type, by Application, by Treatment Type, by End User and Regional Forecasts 2022-2032
»óǰÄÚµå : 1534239
¸®¼­Ä¡»ç : Bizwit Research & Consulting LLP
¹ßÇàÀÏ : 2024³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 285 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,950 £Ü 7,162,000
Unprintable PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 6,250 £Ü 9,043,000
Printable PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

mRNA ¹é½Å ¹× Ä¡·áÁ¦ ¼¼°è ½ÃÀåÀº 2023³â ¾à 468¾ï ´Þ·¯·Î Æò°¡µÇ¸ç, 2024-2032³â ¿¹Ãø ±â°£ µ¿¾È 16.5% ÀÌ»óÀÇ °ßÁ¶ÇÑ ¼ºÀå·üÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

mRNA ±â¹Ý Ä¡·áÁ¦ ¹× ¹é½ÅÀº ±âÁ¸ Ä¡·á¹ýÀ» ´ëüÇÒ ¼ö Àִ ȹ±âÀûÀÎ ´ë¾ÈÀ¸·Î µîÀåÇßÀ¸¸ç, COVID-19 ÆÒµ¥¹Í ±â°£ µ¿¾È COVID-19»Ó¸¸ ¾Æ´Ï¶ó °¨¿°¼º Áúȯ, ¾Ï, À¯Àü¼º Áúȯ µî ´Ù¾çÇÑ Áúº´¿¡ ´ëÇÑ È¿´ÉÀ» ÀÎÁ¤¹ÞÀ¸¸ç Å« ÁöÁö¸¦ ¹Þ¾Ò½À´Ï´Ù.

¸¸¼º Áúȯ°ú °¨¿°¼º ÁúȯÀÇ À¯º´·ü Áõ°¡´Â mRNA ¹é½Å ¹× Ä¡·áÁ¦ ¼¼°è ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Çõ½ÅÀûÀÎ Ä¡·á¹ýÀº ´Ù¾çÇÑ °Ç°­ ¹®Á¦¸¦ ÇØ°áÇÒ ¼ö ÀÖ´Â »õ·Î¿î ¹æ¹ýÀ» Á¦°øÇϱ⠶§¹®ÀÔ´Ï´Ù. ¾Ï, ½ÉÇ÷°üÁúȯ, ´ç´¢º´°ú °°Àº ¸¸¼º ÁúȯÀº Àα¸ °í·ÉÈ­¿Í »ýȰ½À°ü ¿äÀÎÀ¸·Î ÀÎÇØ ´õ¿í ÈçÇØÁö°í ÀÖ½À´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é, ¸¸¼ºÁúȯÀº Àü ¼¼°è »ç¸Á¿øÀÎÀÇ 71%¸¦ Â÷ÁöÇϰí ÀÖ¾î È¿°úÀûÀÎ Ä¡·á¹ýÀÇ Çʿ伺ÀÌ °­Á¶µÇ°í ÀÖ½À´Ï´Ù. µ¿½Ã¿¡ COVID-19¿Í °°Àº Àü¿°º´Àº ½Å¼ÓÇÑ ¹é½Å °³¹ßÀÇ Á߿伺À» °­Á¶Çϰí ÀÖ½À´Ï´Ù. È­ÀÌÀÚ ¹ÙÀÌ¿À¾ØÅ×Å©¿Í Moderna°¡ °³¹ßÇÑ COVID-19 mRNA ¹é½ÅÀÇ ¼º°øÀº °¨¿°º´ À¯Çà¿¡ ½Å¼ÓÇϰí È¿°úÀûÀ¸·Î ´ëÀÀÇÒ ¼ö ÀÖ´Â mRNA ±â¼úÀÇ ÀáÀç·ÂÀ» ÀÔÁõÇß½À´Ï´Ù. ¶ÇÇÑ, ½ÅÈï ½ÃÀå ÁøÃâ, mRNA ÇÕ¼º ¹× Á¦Á¶ ±â¼ú ¹ßÀü, °ø°ø ¹× ¹Î°£ ºÎ¹®ÀÇ ÅõÀÚ Áõ°¡´Â ¿¹Ãø ±â°£ µ¿¾È ´Ù¾çÇÑ À¯¸®ÇÑ ±âȸ¸¦ Á¦°øÇÒ °ÍÀÔ´Ï´Ù. ±×·¯³ª ½ÃÀå ½ÂÀÎÀ» À§ÇÑ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©, ³ôÀº »ý»ê ºñ¿ë, ÀÎÇÁ¶ó ¿ä±¸ »çÇ× µîÀº 2024-2032³â ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀå¿¡ °É¸²µ¹·Î ÀÛ¿ëÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

mRNA ¹é½Å ¹× Ä¡·áÁ¦ ¼¼°è ½ÃÀå Á¶»ç¿¡¼­ °í·ÁµÈ ÁÖ¿ä Áö¿ªÀº ¾Æ½Ã¾ÆÅÂÆò¾ç, ºÏ¹Ì, À¯·´, ¶óƾ¾Æ¸Þ¸®Ä« ¹× ±âŸ Áö¿ªÀÔ´Ï´Ù. ºÏ¹Ì´Â ¼¼°è mRNA ¹é½Å ¹× Ä¡·áÁ¦ ½ÃÀå¿¡¼­ ¼öÀÍ Ãø¸é¿¡¼­ °¡Àå Å« ºñÁßÀ» Â÷ÁöÇÏ´Â Áö¿ªÀÔ´Ï´Ù. ÀÌ Áö¿ªÀÇ ½ÃÀå ¼ºÀåÀº ÷´Ü »ý¸í°øÇÐ ÀÎÇÁ¶ó, R&D¿¡ ´ëÇÑ ¸·´ëÇÑ ÅõÀÚ, Moderna ¹× Pfizer-BioNTech¿Í °°Àº ÁÖ¿ä »ê¾÷ ±â¾÷ÀÇ Á¸Àç¿Í °°Àº ¿äÀο¡ ±âÀÎÇÕ´Ï´Ù. ÀÌ Áö¿ªÀº COVID-19 ÆÒµ¥¹Í ±â°£ µ¿¾È mRNA ¹é½ÅÀÇ °³¹ß ¹× À¯Åë¿¡ ÀÖ¾î ¸®´õ½ÊÀ» ¹ßÈÖÇÏ¿© ±× ÀÔÁö¸¦ È®°íÈ÷ ÇÏ¿´À¸¸ç, ¹Ì±¹ÀÌ ½ÃÀå Á¡À¯À²ÀÇ Å« ºÎºÐÀ» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ÇÑÆí, ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀåÀº ÇコÄɾî ÅõÀÚ Áõ°¡, Çõ½ÅÀûÀÎ Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, mRNA ±â¼úÀÇ ÀáÀçÀû ÀÌÁ¡¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ ¼Óµµ·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Áß±¹, ÀϺ», Çѱ¹°ú °°Àº ±¹°¡µéÀº »ý¸í°øÇп¡ ¸¹Àº ÅõÀÚ¸¦ Çϰí ÀÖÀ¸¸ç, mRNA ±â¹Ý Ä¡·á¹ýÀ» °³¹ßÇÏ°í »ý»êÇÒ ¼ö ÀÖ´Â ´É·ÂÀ» È®ÀåÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå mRNA ¹é½Å ¹× Ä¡·áÁ¦ ¼¼°è ½ÃÀå ÁÖ¿ä ¿ä¾à

Á¦2Àå mRNA ¹é½Å ¹× Ä¡·áÁ¦ ¼¼°è ½ÃÀå Á¤ÀÇ¿Í Á¶»ç °¡Á¤

Á¦3Àå mRNA ¹é½Å ¹× Ä¡·áÁ¦ ¼¼°è ½ÃÀå ¿ªÇÐ

Á¦4Àå ¼¼°èÀÇ mRNA ¹é½Å ¹× Ä¡·áÁ¦ ½ÃÀå »ê¾÷ ºÐ¼®

Á¦5Àå mRNA ¹é½Å ¹× Ä¡·áÁ¦ ¼¼°è ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : ¹é½Å À¯Çüº°, 2022-2032³â

Á¦6Àå mRNA ¹é½Å ¹× Ä¡·áÁ¦ ¼¼°è ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : ¿ëµµº°, 2022-2032³â

Á¦7Àå mRNA ¹é½Å ¹× Ä¡·áÁ¦ ¼¼°è ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : Ä¡·á À¯Çüº°, 2022-2032³â

Á¦8Àå mRNA ¹é½Å ¹× Ä¡·áÁ¦ ¼¼°è ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : ÃÖÁ¾»ç¿ëÀÚº°, 2022-2032³â

Á¦9Àå mRNA ¹é½Å ¹× Ä¡·áÁ¦ ¼¼°è ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : Áö¿ªº°, 2022-2032³â

Á¦10Àå °æÀï Á¤º¸

Á¦11Àå Á¶»ç °úÁ¤

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global mRNA Vaccines and Therapeutics Market is valued at approximately USD 46.8 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 16.5% over the forecast period 2024-2032. Messenger ribonucleic acid (mRNA) represents a single-stranded ribonucleic acid (RNA) type crucial in the transfer of genetic information for protein production. mRNA-based therapeutics and vaccines have surfaced as groundbreaking alternatives to traditional treatment methodologies, gaining immense traction during the COVID-19 pandemic for their efficacy in addressing not only COVID-19 but also a multitude of other conditions including infectious diseases, cancer, and genetic disorders.

The rising prevalence of chronic and infectious diseases is driving significant growth in the global mRNA vaccines and therapeutics market, as these innovative treatments offer new ways to combat a range of health challenges. Chronic diseases such as cancer, cardiovascular diseases, and diabetes are becoming more common due to ageing populations and lifestyle factors. According to the World Health Organization (WHO), chronic diseases account for 71% of all deaths worldwide, highlighting the need for effective treatments. Simultaneously, infectious diseases like COVID-19 have underscored the importance of rapid vaccine development. The success of mRNA vaccines against COVID-19, such as those developed by Pfizer-BioNTech and Moderna, has demonstrated the potential of mRNA technology to quickly and effectively respond to infectious disease outbreaks. Moreover, the expansion into emerging markets, technological advancements in mRNA synthesis and manufacturing, and rising investment from both public and private sectors present various lucrative opportunities over the forecast years. However, the regulatory framework for market authorization, high production costs and infrastructure requirements are challenging the market growth throughout the forecast period of 2024-2032.

The key regions considered for the Global mRNA Vaccines and Therapeutics Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is a dominating region in the Global mRNA Vaccines and Therapeutics Market in terms of revenue. The market growth in the region is being attributed to factors including advanced biotechnology infrastructure, significant investment in research and development, and the presence of key industry players like Moderna and Pfizer-BioNTech. The region's leadership in developing and distributing mRNA vaccines during the COVID-19 pandemic has solidified its position, with the U.S. accounting for a large share of the market. Whereas, the market in Asia Pacific is anticipated to grow at the fastest rate over the forecast period fueled by increasing healthcare investments, rising demand for innovative treatments, and growing awareness of the potential benefits of mRNA technology. Countries such as China, Japan, and South Korea are investing heavily in biotechnology and expanding their capabilities to develop and produce mRNA-based treatments.

Major market players included in this report are:

The detailed segments and sub-segment of the market are explained below:

By Vaccine Type:

By Application:

By Treatment Type:

By End User:

By Region:

North America:

Europe:

Asia Pacific:

Latin America:

Middle East & Africa:

Years considered for the study are as follows:

Key Takeaways:

Table of Contents

Chapter 1. Global mRNA Vaccines and Therapeutics Market Executive Summary

Chapter 2. Global mRNA Vaccines and Therapeutics Market Definition and Research Assumptions

Chapter 3. Global mRNA Vaccines and Therapeutics Market Dynamics

Chapter 4. Global mRNA Vaccines and Therapeutics Market Industry Analysis

Chapter 5. Global mRNA Vaccines and Therapeutics Market Size & Forecasts by Vaccine Type 2022-2032

Chapter 6. Global mRNA Vaccines and Therapeutics Market Size & Forecasts by Application 2022-2032

Chapter 7. Global mRNA Vaccines and Therapeutics Market Size & Forecasts by Treatment Type 2022-2032

Chapter 8. Global mRNA Vaccines and Therapeutics Market Size & Forecasts by End User 2022-2032

Chapter 9. Global mRNA Vaccines and Therapeutics Market Size & Forecasts by Region 2022-2032

Chapter 10. Competitive Intelligence

Chapter 11. Research Process

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â